Open-mkt buys · 90d
—
0 trades · 0 insiders
Open-mkt sales · 90d
—
0 trades · 0 insiders
Net · 90d
$0
Insiders on file
22
Daily buy vs sell · 90 days
No data yet.
Insiders
| Insider | Role | Trades | Bought | Sold | Last trade |
|---|---|---|---|---|---|
| Benny Paul S. | VP, Treasurer | 15 | $0 | $0 | 2023-01-05 |
| Steinway Angela | Director | 3 | $0 | $0 | 2023-01-05 |
| Standish Beau | President, Enabling Tech | 12 | $0 | $977.6K | 2023-01-05 |
| Maniar Shweta | Director | 5 | $0 | $30.3K | 2023-01-05 |
| Cirino Dennis | Senior VP, Spinal Systems | 52 | $0 | $0 | 2023-01-05 |
| Gaeta Renee | Director | 16 | $0 | $179.5K | 2023-01-05 |
| Bostjancic John J. | Chief Financial Officer | 76 | $114.1K | $0 | 2023-01-05 |
| Winge John J. | Vice President, Sales | 82 | $80.8K | $21.5K | 2023-01-05 |
| Stephenson Kirtley C. | Director | 21 | $149.3K | $0 | 2023-01-05 |
| FEKETE MICHAEL | Director | 23 | $197.2K | $0 | 2023-01-05 |
| Lipschultz Tyler | SVP, Orthobiologics and BD | 57 | $0 | $0 | 2023-01-05 |
| Keran Patrick L | VP, General Counsel | 66 | $0 | $42.1K | 2023-01-05 |
| Valentine Keith | Chief Executive Officer | 78 | $1.50M | $0 | 2023-01-05 |
| BRADLEY KEITH | Director | 51 | $0 | $31.2K | 2023-01-05 |
| ESSIG STUART | Director | 41 | $1.33M | $1.66M | 2023-01-05 |
| HENNEMAN JOHN B III | Director | 21 | $0 | $296.8K | 2023-01-05 |
| TZOUMAKAS KIMBERLY JO | Director | 3 | $0 | $0 | 2020-06-03 |
| CARUSO RICHARD E | 10% Owner | 6 | $0 | $128.1K | 2020-04-29 |
| Blanchard Cheryl R | Director | 4 | $0 | $0 | 2018-05-30 |
| SULLIVAN JAMES M | Director | 10 | $0 | $0 | 2018-05-30 |
| Baker Brian D. | VP, Global Operations | 16 | $68.8K | $27.3K | 2018-01-26 |
| Integra LifeSciences Corp | 10% Owner | 1 | $0 | $0 | 2015-07-01 |
Trade history
| Insider | Role | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|---|
| Valentine Keith | Chief Executive Officer | D To issuer deriv | 2023-01-05 | 2023-01-09 | 77,881 | — | $0 | 0 | SEC↗ |
| Valentine Keith | Chief Executive Officer | D To issuer deriv | 2023-01-05 | 2023-01-09 | 261,699 | — | $0 | 0 | SEC↗ |
| Valentine Keith | Chief Executive Officer | D To issuer deriv | 2023-01-05 | 2023-01-09 | 8,871 | — | $0 | 0 | SEC↗ |
| Valentine Keith | Chief Executive Officer | D To issuer deriv | 2023-01-05 | 2023-01-09 | 121,830 | — | $0 | 0 | SEC↗ |
| Valentine Keith | Chief Executive Officer | D To issuer deriv | 2023-01-05 | 2023-01-09 | 31,866 | — | $0 | 0 | SEC↗ |
| Valentine Keith | Chief Executive Officer | D To issuer deriv | 2023-01-05 | 2023-01-09 | 149,074 | — | $0 | 0 | SEC↗ |
| Valentine Keith | Chief Executive Officer | D To issuer deriv | 2023-01-05 | 2023-01-09 | 325,000 | — | $0 | 0 | SEC↗ |
| Valentine Keith | Chief Executive Officer | D To issuer deriv | 2023-01-05 | 2023-01-09 | 236,779 | — | $0 | 0 | SEC↗ |
| Valentine Keith | Chief Executive Officer | D To issuer deriv | 2023-01-05 | 2023-01-09 | 52,392 | — | $0 | 0 | SEC↗ |
| Bostjancic John J. | Chief Financial Officer | D To issuer deriv | 2023-01-05 | 2023-01-09 | 55,746 | — | $0 | 0 | SEC↗ |
| Bostjancic John J. | Chief Financial Officer | D To issuer deriv | 2023-01-05 | 2023-01-09 | 17,818 | — | $0 | 0 | SEC↗ |
| Bostjancic John J. | Chief Financial Officer | D To issuer deriv | 2023-01-05 | 2023-01-09 | 64,599 | — | $0 | 0 | SEC↗ |
| Bostjancic John J. | Chief Financial Officer | D To issuer deriv | 2023-01-05 | 2023-01-09 | 62,000 | — | $0 | 0 | SEC↗ |
| Bostjancic John J. | Chief Financial Officer | D To issuer deriv | 2023-01-05 | 2023-01-09 | 6,089 | — | $0 | 0 | SEC↗ |
| Bostjancic John J. | Chief Financial Officer | D To issuer deriv | 2023-01-05 | 2023-01-09 | 13,840 | — | $0 | 0 | SEC↗ |
| Bostjancic John J. | Chief Financial Officer | D To issuer deriv | 2023-01-05 | 2023-01-09 | 51,795 | — | $0 | 0 | SEC↗ |
| Bostjancic John J. | Chief Financial Officer | D To issuer deriv | 2023-01-05 | 2023-01-09 | 21,704 | — | $0 | 0 | SEC↗ |
| Bostjancic John J. | Chief Financial Officer | D To issuer deriv | 2023-01-05 | 2023-01-09 | 43,163 | — | $0 | 0 | SEC↗ |
| Bostjancic John J. | Chief Financial Officer | D To issuer deriv | 2023-01-05 | 2023-01-09 | 69,128 | — | $0 | 0 | SEC↗ |
| Benny Paul S. | VP, Treasurer | D To issuer deriv | 2023-01-05 | 2023-01-09 | 8,800 | — | $0 | 0 | SEC↗ |
| Benny Paul S. | VP, Treasurer | D To issuer deriv | 2023-01-05 | 2023-01-09 | 1,186 | — | $0 | 0 | SEC↗ |
| Benny Paul S. | VP, Treasurer | D To issuer deriv | 2023-01-05 | 2023-01-09 | 2,762 | — | $0 | 0 | SEC↗ |
| Benny Paul S. | VP, Treasurer | D To issuer deriv | 2023-01-05 | 2023-01-09 | 5,925 | — | $0 | 0 | SEC↗ |
| Benny Paul S. | VP, Treasurer | D To issuer deriv | 2023-01-05 | 2023-01-09 | 2,716 | — | $0 | 0 | SEC↗ |
| Benny Paul S. | VP, Treasurer | D To issuer deriv | 2023-01-05 | 2023-01-09 | 10,398 | — | $0 | 0 | SEC↗ |
| Benny Paul S. | VP, Treasurer | D To issuer deriv | 2023-01-05 | 2023-01-09 | 3,423 | — | $0 | 0 | SEC↗ |
| Benny Paul S. | VP, Treasurer | D To issuer deriv | 2023-01-05 | 2023-01-09 | 6,906 | — | $0 | 0 | SEC↗ |
| Benny Paul S. | VP, Treasurer | D To issuer deriv | 2023-01-05 | 2023-01-09 | 10,000 | — | $0 | 0 | SEC↗ |
| Cirino Dennis | SVP, Global Spinal Systems | D To issuer deriv | 2023-01-05 | 2023-01-09 | 19,652 | — | $0 | 0 | SEC↗ |
| Cirino Dennis | SVP, Global Spinal Systems | D To issuer deriv | 2023-01-05 | 2023-01-09 | 20,619 | — | $0 | 0 | SEC↗ |
| Cirino Dennis | SVP, Global Spinal Systems | D To issuer deriv | 2023-01-05 | 2023-01-09 | 41,229 | — | $0 | 0 | SEC↗ |
| Cirino Dennis | SVP, Global Spinal Systems | D To issuer deriv | 2023-01-05 | 2023-01-09 | 5,845 | — | $0 | 0 | SEC↗ |
| Cirino Dennis | SVP, Global Spinal Systems | D To issuer deriv | 2023-01-05 | 2023-01-09 | 53,518 | — | $0 | 0 | SEC↗ |
| Cirino Dennis | SVP, Global Spinal Systems | D To issuer deriv | 2023-01-05 | 2023-01-09 | 11,804 | — | $0 | 0 | SEC↗ |
| Cirino Dennis | SVP, Global Spinal Systems | D To issuer deriv | 2023-01-05 | 2023-01-09 | 16,492 | — | $0 | 0 | SEC↗ |
| Cirino Dennis | SVP, Global Spinal Systems | D To issuer deriv | 2023-01-05 | 2023-01-09 | 34,211 | — | $0 | 0 | SEC↗ |
| Keran Patrick L | SVP, General Counsel | D To issuer deriv | 2023-01-05 | 2023-01-09 | 21,704 | — | $0 | 0 | SEC↗ |
| Keran Patrick L | SVP, General Counsel | D To issuer deriv | 2023-01-05 | 2023-01-09 | 60,000 | — | $0 | 0 | SEC↗ |
| Keran Patrick L | SVP, General Counsel | D To issuer deriv | 2023-01-05 | 2023-01-09 | 64,599 | — | $0 | 0 | SEC↗ |
| Keran Patrick L | SVP, General Counsel | D To issuer deriv | 2023-01-05 | 2023-01-09 | 33,749 | — | $0 | 0 | SEC↗ |
| Keran Patrick L | SVP, General Counsel | D To issuer deriv | 2023-01-05 | 2023-01-09 | 52,797 | — | $0 | 0 | SEC↗ |
| Keran Patrick L | SVP, General Counsel | D To issuer deriv | 2023-01-05 | 2023-01-09 | 6,045 | — | $0 | 0 | SEC↗ |
| Keran Patrick L | SVP, General Counsel | D To issuer deriv | 2023-01-05 | 2023-01-09 | 40,786 | — | $0 | 0 | SEC↗ |
| Keran Patrick L | SVP, General Counsel | D To issuer deriv | 2023-01-05 | 2023-01-09 | 8,166 | — | $0 | 0 | SEC↗ |
| Keran Patrick L | SVP, General Counsel | D To issuer deriv | 2023-01-05 | 2023-01-09 | 52,091 | — | $0 | 0 | SEC↗ |
| Lipschultz Tyler | SVP, Orthobiologics and BD | D To issuer deriv | 2023-01-05 | 2023-01-09 | 6,089 | — | $0 | 0 | SEC↗ |
| Lipschultz Tyler | SVP, Orthobiologics and BD | D To issuer deriv | 2023-01-05 | 2023-01-09 | 27,873 | — | $0 | 0 | SEC↗ |
| Lipschultz Tyler | SVP, Orthobiologics and BD | D To issuer deriv | 2023-01-05 | 2023-01-09 | 16,196 | — | $0 | 0 | SEC↗ |
| Lipschultz Tyler | SVP, Orthobiologics and BD | D To issuer deriv | 2023-01-05 | 2023-01-09 | 64,599 | — | $0 | 0 | SEC↗ |
| Lipschultz Tyler | SVP, Orthobiologics and BD | D To issuer deriv | 2023-01-05 | 2023-01-09 | 21,236 | — | $0 | 0 | SEC↗ |
| Lipschultz Tyler | SVP, Orthobiologics and BD | D To issuer deriv | 2023-01-05 | 2023-01-09 | 60,000 | — | $0 | 0 | SEC↗ |
| Lipschultz Tyler | SVP, Orthobiologics and BD | D To issuer deriv | 2023-01-05 | 2023-01-09 | 33,977 | — | $0 | 0 | SEC↗ |
| Lipschultz Tyler | SVP, Orthobiologics and BD | D To issuer deriv | 2023-01-05 | 2023-01-09 | 12,970 | — | $0 | 0 | SEC↗ |
| Lipschultz Tyler | SVP, Orthobiologics and BD | D To issuer deriv | 2023-01-05 | 2023-01-09 | 35,636 | — | $0 | 0 | SEC↗ |
| Standish Beau | President, Enabling Tech | D To issuer deriv | 2023-01-05 | 2023-01-09 | 100,000 | — | $0 | 0 | SEC↗ |
| Standish Beau | President, Enabling Tech | D To issuer deriv | 2023-01-05 | 2023-01-09 | 14,108 | — | $0 | 0 | SEC↗ |
| Winge John J. | Vice President, Sales | D To issuer deriv | 2023-01-05 | 2023-01-09 | 18,912 | — | $0 | 0 | SEC↗ |
| Winge John J. | Vice President, Sales | D To issuer deriv | 2023-01-05 | 2023-01-09 | 5,342 | — | $0 | 0 | SEC↗ |
| Winge John J. | Vice President, Sales | D To issuer deriv | 2023-01-05 | 2023-01-09 | 48,678 | — | $0 | 0 | SEC↗ |
| Winge John J. | Vice President, Sales | D To issuer deriv | 2023-01-05 | 2023-01-09 | 31,118 | — | $0 | 0 | SEC↗ |
| Winge John J. | Vice President, Sales | D To issuer deriv | 2023-01-05 | 2023-01-09 | 59,562 | — | $0 | 0 | SEC↗ |
| Winge John J. | Vice President, Sales | D To issuer deriv | 2023-01-05 | 2023-01-09 | 40,000 | — | $0 | 0 | SEC↗ |
| Winge John J. | Vice President, Sales | D To issuer deriv | 2023-01-05 | 2023-01-09 | 30,248 | — | $0 | 0 | SEC↗ |
| Winge John J. | Vice President, Sales | D To issuer deriv | 2023-01-05 | 2023-01-09 | 14,432 | — | $0 | 0 | SEC↗ |
| ESSIG STUART | Director | D To issuer deriv | 2023-01-05 | 2023-01-09 | 25,056 | — | $0 | 0 | SEC↗ |
| ESSIG STUART | Director | D To issuer deriv | 2023-01-05 | 2023-01-09 | 6,944 | — | $0 | 0 | SEC↗ |
| ESSIG STUART | Director | D To issuer deriv | 2023-01-05 | 2023-01-09 | 98,198 | — | $0 | 0 | SEC↗ |
| BRADLEY KEITH | Director | D To issuer deriv | 2023-01-05 | 2023-01-09 | 58,559 | — | $0 | 0 | SEC↗ |
| BRADLEY KEITH | Director | D To issuer deriv | 2023-01-05 | 2023-01-09 | 13,920 | — | $0 | 0 | SEC↗ |
| BRADLEY KEITH | Director | D To issuer deriv | 2023-01-05 | 2023-01-09 | 3,858 | — | $0 | 0 | SEC↗ |
| HENNEMAN JOHN B III | Director | D To issuer deriv | 2023-01-05 | 2023-01-09 | 3,858 | — | $0 | 0 | SEC↗ |
| HENNEMAN JOHN B III | Director | D To issuer deriv | 2023-01-05 | 2023-01-09 | 58,559 | — | $0 | 0 | SEC↗ |
| HENNEMAN JOHN B III | Director | D To issuer deriv | 2023-01-05 | 2023-01-09 | 13,920 | — | $0 | 0 | SEC↗ |
| FEKETE MICHAEL | Director | D To issuer deriv | 2023-01-05 | 2023-01-09 | 5,015 | — | $0 | 0 | SEC↗ |
| FEKETE MICHAEL | Director | D To issuer deriv | 2023-01-05 | 2023-01-09 | 18,096 | — | $0 | 0 | SEC↗ |
| FEKETE MICHAEL | Director | D To issuer deriv | 2023-01-05 | 2023-01-09 | 59,910 | — | $0 | 0 | SEC↗ |
| Stephenson Kirtley C. | Director | D To issuer deriv | 2023-01-05 | 2023-01-09 | 117,117 | — | $0 | 0 | SEC↗ |
| Valentine Keith | Chief Executive Officer | D To issuer | 2023-01-05 | 2023-01-09 | 333,797 | — | $0 | 0 | SEC↗ |
| Bostjancic John J. | Chief Financial Officer | D To issuer | 2023-01-05 | 2023-01-09 | 102,563 | — | $0 | 0 | SEC↗ |
| Benny Paul S. | VP, Treasurer | D To issuer | 2023-01-05 | 2023-01-09 | 20,950 | — | $0 | 0 | SEC↗ |
| Cirino Dennis | SVP, Global Spinal Systems | D To issuer | 2023-01-05 | 2023-01-09 | 48,556 | — | $0 | 0 | SEC↗ |
| Keran Patrick L | SVP, General Counsel | D To issuer | 2023-01-05 | 2023-01-09 | 69,628 | — | $0 | 0 | SEC↗ |
| Lipschultz Tyler | SVP, Orthobiologics and BD | D To issuer | 2023-01-05 | 2023-01-09 | 131,284 | — | $0 | 0 | SEC↗ |
| Winge John J. | Vice President, Sales | D To issuer | 2023-01-05 | 2023-01-09 | 90,951 | — | $0 | 0 | SEC↗ |
| ESSIG STUART | Director | D To issuer | 2023-01-05 | 2023-01-09 | 460,275 | — | $0 | 0 | SEC↗ |
| BRADLEY KEITH | Director | D To issuer | 2023-01-05 | 2023-01-09 | 88,592 | — | $0 | 0 | SEC↗ |
| HENNEMAN JOHN B III | Director | D To issuer | 2023-01-05 | 2023-01-09 | 82,654 | — | $0 | 0 | SEC↗ |
| FEKETE MICHAEL | Director | D To issuer | 2023-01-05 | 2023-01-09 | 111,966 | — | $0 | 0 | SEC↗ |
| Gaeta Renee | Director | D To issuer | 2023-01-05 | 2023-01-09 | 36,056 | — | $0 | 0 | SEC↗ |
| Maniar Shweta | Director | D To issuer | 2023-01-05 | 2023-01-09 | 23,993 | — | $0 | 0 | SEC↗ |
| Steinway Angela | Director | D To issuer | 2023-01-05 | 2023-01-09 | 23,725 | — | $0 | 0 | SEC↗ |
| Stephenson Kirtley C. | Director | D To issuer | 2023-01-05 | 2023-01-09 | 128,640 | — | $0 | 0 | SEC↗ |
| Stephenson Kirtley C. | Director | D To issuer | 2023-01-05 | 2023-01-09 | 9,700 | — | $0 | 0 | SEC↗ |
| Valentine Keith | Chief Executive Officer | M Exercise deriv | 2023-01-01 | 2023-01-03 | 12,183 | — | $0 | 0 | SEC↗ |
| Bostjancic John J. | Chief Financial Officer | M Exercise deriv | 2023-01-01 | 2023-01-03 | 5,575 | — | $0 | 0 | SEC↗ |
| Benny Paul S. | VP, Treasurer | M Exercise deriv | 2023-01-01 | 2023-01-03 | 1,041 | — | $0 | 0 | SEC↗ |
| Cirino Dennis | SVP, Global Spinal Systems | M Exercise deriv | 2023-01-01 | 2023-01-03 | 5,352 | — | $0 | 0 | SEC↗ |
| Keran Patrick L | SVP, General Counsel | M Exercise deriv | 2023-01-01 | 2023-01-03 | 5,280 | — | $0 | 0 | SEC↗ |
| Lipschultz Tyler | SVP, Orthobiologics and BD | M Exercise deriv | 2023-01-01 | 2023-01-03 | 8,362 | — | $0 | 0 | SEC↗ |
| Winge John J. | Vice President, Sales | M Exercise deriv | 2023-01-01 | 2023-01-03 | 4,868 | — | $0 | 0 | SEC↗ |
| Valentine Keith | Chief Executive Officer | F Tax w/h | 2023-01-01 | 2023-01-03 | 7,170 | $8.35 | $59.9K | 333,797 | SEC↗ |
| Valentine Keith | Chief Executive Officer | M Exercise | 2023-01-01 | 2023-01-03 | 12,183 | — | $0 | 340,967 | SEC↗ |
| Bostjancic John J. | Chief Financial Officer | F Tax w/h | 2023-01-01 | 2023-01-03 | 3,281 | $8.35 | $27.4K | 102,563 | SEC↗ |
| Bostjancic John J. | Chief Financial Officer | M Exercise | 2023-01-01 | 2023-01-03 | 5,575 | — | $0 | 105,844 | SEC↗ |
| Benny Paul S. | VP, Treasurer | M Exercise | 2023-01-01 | 2023-01-03 | 1,041 | — | $0 | 21,375 | SEC↗ |
| Benny Paul S. | VP, Treasurer | F Tax w/h | 2023-01-01 | 2023-01-03 | 425 | $8.35 | $3.5K | 20,950 | SEC↗ |
| Cirino Dennis | SVP, Global Spinal Systems | F Tax w/h | 2023-01-01 | 2023-01-03 | 3,150 | $8.35 | $26.3K | 48,556 | SEC↗ |
| Cirino Dennis | SVP, Global Spinal Systems | M Exercise | 2023-01-01 | 2023-01-03 | 5,352 | — | $0 | 51,706 | SEC↗ |
| Keran Patrick L | SVP, General Counsel | M Exercise | 2023-01-01 | 2023-01-03 | 5,280 | — | $0 | 72,736 | SEC↗ |
| Keran Patrick L | SVP, General Counsel | F Tax w/h | 2023-01-01 | 2023-01-03 | 3,108 | $8.35 | $26.0K | 69,628 | SEC↗ |
| Lipschultz Tyler | SVP, Orthobiologics and BD | F Tax w/h | 2023-01-01 | 2023-01-03 | 3,411 | $8.35 | $28.5K | 131,284 | SEC↗ |
| Lipschultz Tyler | SVP, Orthobiologics and BD | M Exercise | 2023-01-01 | 2023-01-03 | 8,362 | — | $0 | 134,695 | SEC↗ |
| Winge John J. | Vice President, Sales | M Exercise | 2023-01-01 | 2023-01-03 | 4,868 | — | $0 | 93,441 | SEC↗ |
| Winge John J. | Vice President, Sales | F Tax w/h | 2023-01-01 | 2023-01-03 | 2,490 | $8.35 | $20.8K | 90,951 | SEC↗ |
| Maniar Shweta | Director | S Sale | 2022-12-29 | 2022-12-30 | 3,786 | $8.00 | $30.3K | 23,993 | SEC↗ |
| Lipschultz Tyler | SVP, Orthobiologics and BD | J Other | 2022-12-28 | 2022-12-30 | 2,500 | $4.92 | $12.3K | 126,333 | SEC↗ |
| Benny Paul S. | VP, Treasurer | J Other | 2022-12-28 | 2022-12-30 | 1,320 | $4.92 | $6.5K | 20,334 | SEC↗ |
| Standish Beau | President, Enabling Tech | C Conversion deriv | 2022-11-08 | 2022-11-08 | 254,950 | — | $0 | 0 | SEC↗ |
| Standish Beau | President, Enabling Tech | C Conversion | 2022-11-08 | 2022-11-08 | 254,950 | — | $0 | 254,950 | SEC↗ |
| Standish Beau | President, Enabling Tech | S Sale | 2022-07-14 | 2022-07-15 | 50,000 | $5.73 | $286.5K | 0 | SEC↗ |
| Valentine Keith | Chief Executive Officer | J Other | 2022-06-30 | 2022-07-01 | 2,385 | $4.80 | $11.4K | 328,784 | SEC↗ |
| Benny Paul S. | VP, Treasurer | J Other | 2022-06-30 | 2022-07-01 | 1,261 | $4.80 | $6.1K | 19,014 | SEC↗ |
| Cirino Dennis | SVP, Global Spinal Systems | J Other | 2022-06-30 | 2022-07-01 | 2,384 | $4.80 | $11.4K | 46,354 | SEC↗ |
| Winge John J. | Vice President, Sales | J Other | 2022-06-30 | 2022-07-01 | 1,785 | $4.80 | $8.6K | 88,573 | SEC↗ |
| BRADLEY KEITH | Director | F Tax w/h | 2022-06-02 | 2022-06-03 | 319 | $7.77 | $2.5K | 88,592 | SEC↗ |
| Stephenson Kirtley C. | Director | A Award | 2022-06-01 | 2022-06-03 | 22,321 | — | $0 | 128,640 | SEC↗ |
| BRADLEY KEITH | Director | A Award | 2022-06-01 | 2022-06-03 | 15,943 | — | $0 | 88,911 | SEC↗ |
| ESSIG STUART | Director | A Award | 2022-06-01 | 2022-06-03 | 15,943 | — | $0 | 460,275 | SEC↗ |
| FEKETE MICHAEL | Director | A Award | 2022-06-01 | 2022-06-03 | 7,653 | — | $0 | 111,966 | SEC↗ |
| FEKETE MICHAEL | Director | A Award | 2022-06-01 | 2022-06-03 | 15,943 | — | $0 | 104,313 | SEC↗ |
| Gaeta Renee | Director | A Award | 2022-06-01 | 2022-06-03 | 15,943 | — | $0 | 36,056 | SEC↗ |
| HENNEMAN JOHN B III | Director | A Award | 2022-06-01 | 2022-06-03 | 15,943 | — | $0 | 82,654 | SEC↗ |
| Maniar Shweta | Director | A Award | 2022-06-01 | 2022-06-03 | 15,943 | — | $0 | 27,779 | SEC↗ |
| Steinway Angela | Director | A Award | 2022-06-01 | 2022-06-03 | 15,943 | — | $0 | 23,725 | SEC↗ |
| Gaeta Renee | Director | S Sale | 2022-03-14 | 2022-03-15 | 2,000 | $12.03 | $24.1K | 20,113 | SEC↗ |
| BRADLEY KEITH | Director | F Tax w/h | 2022-03-02 | 2022-03-04 | 37 | $13.25 | $490 | 72,968 | SEC↗ |
| Valentine Keith | Chief Executive Officer | A Award deriv | 2022-02-28 | 2022-03-02 | 31,866 | — | $0 | 31,866 | SEC↗ |
| Valentine Keith | Chief Executive Officer | A Award deriv | 2022-02-28 | 2022-03-02 | 236,779 | — | $0 | 236,779 | SEC↗ |
| Bostjancic John J. | Chief Financial Officer | A Award deriv | 2022-02-28 | 2022-03-02 | 51,795 | — | $0 | 51,795 | SEC↗ |
| Bostjancic John J. | Chief Financial Officer | A Award deriv | 2022-02-28 | 2022-03-02 | 43,163 | — | $0 | 43,163 | SEC↗ |
| Bostjancic John J. | Chief Financial Officer | A Award deriv | 2022-02-28 | 2022-03-02 | 21,704 | — | $0 | 21,704 | SEC↗ |
| Cirino Dennis | SVP, Global Spinal Systems | A Award deriv | 2022-02-28 | 2022-03-02 | 20,619 | — | $0 | 20,619 | SEC↗ |
| Cirino Dennis | SVP, Global Spinal Systems | A Award deriv | 2022-02-28 | 2022-03-02 | 41,229 | — | $0 | 41,229 | SEC↗ |
| Cirino Dennis | SVP, Global Spinal Systems | A Award deriv | 2022-02-28 | 2022-03-02 | 16,492 | — | $0 | 16,492 | SEC↗ |
| Keran Patrick L | SVP, General Counsel | A Award deriv | 2022-02-28 | 2022-03-02 | 52,091 | — | $0 | 52,091 | SEC↗ |
| Keran Patrick L | SVP, General Counsel | A Award deriv | 2022-02-28 | 2022-03-02 | 21,704 | — | $0 | 21,704 | SEC↗ |
| Lipschultz Tyler | SVP, Orthobiologics and BD | A Award deriv | 2022-02-28 | 2022-03-02 | 21,236 | — | $0 | 21,236 | SEC↗ |
| Lipschultz Tyler | SVP, Orthobiologics and BD | A Award deriv | 2022-02-28 | 2022-03-02 | 33,977 | — | $0 | 33,977 | SEC↗ |
| Standish Beau | President, Enabling Tech | A Award deriv | 2022-02-28 | 2022-03-02 | 14,108 | — | $0 | 14,108 | SEC↗ |
| Winge John J. | Vice President, Sales | A Award deriv | 2022-02-28 | 2022-03-02 | 30,248 | — | $0 | 30,248 | SEC↗ |
| Winge John J. | Vice President, Sales | A Award deriv | 2022-02-28 | 2022-03-02 | 18,912 | — | $0 | 18,912 | SEC↗ |
| Gaeta Renee | Director | S Sale | 2022-02-14 | 2022-02-16 | 2,000 | $12.06 | $24.1K | 22,113 | SEC↗ |
| Valentine Keith | Chief Executive Officer | M Exercise deriv | 2022-01-28 | 2022-02-01 | 26,196 | — | $0 | 52,392 | SEC↗ |
| Bostjancic John J. | Chief Financial Officer | M Exercise deriv | 2022-01-28 | 2022-02-01 | 6,919 | — | $0 | 13,840 | SEC↗ |
| Cirino Dennis | SVP, Global Spinal Systems | M Exercise deriv | 2022-01-28 | 2022-02-01 | 5,901 | — | $0 | 11,804 | SEC↗ |
| Keran Patrick L | SVP, General Counsel | M Exercise deriv | 2022-01-28 | 2022-02-01 | 4,082 | — | $0 | 8,166 | SEC↗ |
| Lipschultz Tyler | SVP, Orthobiologics and BD | M Exercise deriv | 2022-01-28 | 2022-02-01 | 6,484 | — | $0 | 12,970 | SEC↗ |
| Winge John J. | Vice President, Sales | M Exercise deriv | 2022-01-28 | 2022-02-01 | 7,216 | — | $0 | 14,432 | SEC↗ |
| Valentine Keith | Chief Executive Officer | F Tax w/h | 2022-01-28 | 2022-02-01 | 13,798 | $11.39 | $157.2K | 326,399 | SEC↗ |
| Valentine Keith | Chief Executive Officer | M Exercise | 2022-01-28 | 2022-02-01 | 26,196 | — | $0 | 340,197 | SEC↗ |
| Bostjancic John J. | Chief Financial Officer | F Tax w/h | 2022-01-28 | 2022-02-01 | 3,628 | $11.39 | $41.3K | 100,269 | SEC↗ |
| Bostjancic John J. | Chief Financial Officer | M Exercise | 2022-01-28 | 2022-02-01 | 6,919 | — | $0 | 103,897 | SEC↗ |
| Cirino Dennis | SVP, Global Spinal Systems | M Exercise | 2022-01-28 | 2022-02-01 | 5,901 | — | $0 | 47,037 | SEC↗ |
| Cirino Dennis | SVP, Global Spinal Systems | F Tax w/h | 2022-01-28 | 2022-02-01 | 3,067 | $11.39 | $34.9K | 43,970 | SEC↗ |
| Keran Patrick L | SVP, General Counsel | F Tax w/h | 2022-01-28 | 2022-02-01 | 2,113 | $11.39 | $24.1K | 67,456 | SEC↗ |
| Keran Patrick L | SVP, General Counsel | M Exercise | 2022-01-28 | 2022-02-01 | 4,082 | — | $0 | 69,569 | SEC↗ |
| Lipschultz Tyler | SVP, Orthobiologics and BD | F Tax w/h | 2022-01-28 | 2022-02-01 | 2,243 | $11.39 | $25.5K | 123,833 | SEC↗ |
| Lipschultz Tyler | SVP, Orthobiologics and BD | M Exercise | 2022-01-28 | 2022-02-01 | 6,484 | — | $0 | 126,076 | SEC↗ |
| Winge John J. | Vice President, Sales | F Tax w/h | 2022-01-28 | 2022-02-01 | 2,235 | $11.39 | $25.5K | 86,788 | SEC↗ |
| Winge John J. | Vice President, Sales | M Exercise | 2022-01-28 | 2022-02-01 | 7,216 | — | $0 | 89,023 | SEC↗ |
| Standish Beau | President, Enabling Tech | C Conversion deriv | 2022-01-27 | 2022-02-11 | 50,000 | — | $0 | 254,950 | SEC↗ |
| Standish Beau | President, Enabling Tech | C Conversion | 2022-01-27 | 2022-02-11 | 50,000 | — | $0 | 50,000 | SEC↗ |
| Gaeta Renee | Director | S Sale | 2022-01-10 | 2022-01-10 | 2,000 | $12.35 | $24.7K | 24,113 | SEC↗ |
| Valentine Keith | Chief Executive Officer | M Exercise deriv | 2022-01-01 | 2022-01-04 | 7,789 | — | $0 | 0 | SEC↗ |
| Valentine Keith | Chief Executive Officer | M Exercise deriv | 2022-01-01 | 2022-01-04 | 12,183 | — | $0 | 12,183 | SEC↗ |
| Winge John J. | Vice President, Sales | M Exercise deriv | 2022-01-01 | 2022-01-04 | 4,868 | — | $0 | 4,868 | SEC↗ |
| Winge John J. | Vice President, Sales | M Exercise deriv | 2022-01-01 | 2022-01-04 | 3,112 | — | $0 | 0 | SEC↗ |
| Bostjancic John J. | Chief Financial Officer | M Exercise deriv | 2022-01-01 | 2022-01-04 | 5,575 | — | $0 | 5,575 | SEC↗ |
| Bostjancic John J. | Chief Financial Officer | M Exercise deriv | 2022-01-01 | 2022-01-04 | 5,346 | — | $0 | 0 | SEC↗ |
| Cirino Dennis | SVP, Global Spinal Systems | M Exercise deriv | 2022-01-01 | 2022-01-04 | 5,352 | — | $0 | 5,352 | SEC↗ |
| Cirino Dennis | SVP, Global Spinal Systems | M Exercise deriv | 2022-01-01 | 2022-01-04 | 3,422 | — | $0 | 0 | SEC↗ |
| Keran Patrick L | SVP, General Counsel | M Exercise deriv | 2022-01-01 | 2022-01-04 | 3,375 | — | $0 | 0 | SEC↗ |
| Keran Patrick L | SVP, General Counsel | M Exercise deriv | 2022-01-01 | 2022-01-04 | 5,280 | — | $0 | 5,280 | SEC↗ |
| Lipschultz Tyler | SVP, Orthobiologics and BD | M Exercise deriv | 2022-01-01 | 2022-01-04 | 8,362 | — | $0 | 8,362 | SEC↗ |
| Lipschultz Tyler | SVP, Orthobiologics and BD | M Exercise deriv | 2022-01-01 | 2022-01-04 | 3,564 | — | $0 | 0 | SEC↗ |
| Valentine Keith | Chief Executive Officer | F Tax w/h | 2022-01-01 | 2022-01-04 | 11,167 | $13.62 | $152.1K | 314,001 | SEC↗ |
| Valentine Keith | Chief Executive Officer | M Exercise | 2022-01-01 | 2022-01-04 | 12,183 | — | $0 | 325,168 | SEC↗ |
| Valentine Keith | Chief Executive Officer | M Exercise | 2022-01-01 | 2022-01-04 | 7,789 | — | $0 | 312,985 | SEC↗ |
| Winge John J. | Vice President, Sales | M Exercise | 2022-01-01 | 2022-01-04 | 3,112 | — | $0 | 81,022 | SEC↗ |
| Winge John J. | Vice President, Sales | M Exercise | 2022-01-01 | 2022-01-04 | 4,868 | — | $0 | 85,890 | SEC↗ |
| Winge John J. | Vice President, Sales | F Tax w/h | 2022-01-01 | 2022-01-04 | 4,083 | $13.62 | $55.6K | 81,807 | SEC↗ |
| Bostjancic John J. | Chief Financial Officer | M Exercise | 2022-01-01 | 2022-01-04 | 5,575 | — | $0 | 103,418 | SEC↗ |
| Bostjancic John J. | Chief Financial Officer | M Exercise | 2022-01-01 | 2022-01-04 | 5,346 | — | $0 | 97,843 | SEC↗ |
| Bostjancic John J. | Chief Financial Officer | F Tax w/h | 2022-01-01 | 2022-01-04 | 6,440 | $13.62 | $87.7K | 96,978 | SEC↗ |
| Cirino Dennis | SVP, Global Spinal Systems | M Exercise | 2022-01-01 | 2022-01-04 | 3,422 | — | $0 | 40,967 | SEC↗ |
| Cirino Dennis | SVP, Global Spinal Systems | M Exercise | 2022-01-01 | 2022-01-04 | 5,352 | — | $0 | 46,319 | SEC↗ |
| Cirino Dennis | SVP, Global Spinal Systems | F Tax w/h | 2022-01-01 | 2022-01-04 | 5,183 | $13.62 | $70.6K | 41,136 | SEC↗ |
| Keran Patrick L | SVP, General Counsel | F Tax w/h | 2022-01-01 | 2022-01-04 | 5,121 | $13.62 | $69.7K | 65,487 | SEC↗ |
| Keran Patrick L | SVP, General Counsel | M Exercise | 2022-01-01 | 2022-01-04 | 5,280 | — | $0 | 70,608 | SEC↗ |
| Keran Patrick L | SVP, General Counsel | M Exercise | 2022-01-01 | 2022-01-04 | 3,375 | — | $0 | 65,328 | SEC↗ |
| Lipschultz Tyler | SVP, Orthobiologics and BD | F Tax w/h | 2022-01-01 | 2022-01-04 | 4,801 | $13.62 | $65.4K | 119,592 | SEC↗ |
| Lipschultz Tyler | SVP, Orthobiologics and BD | M Exercise | 2022-01-01 | 2022-01-04 | 8,362 | — | $0 | 124,393 | SEC↗ |
| Lipschultz Tyler | SVP, Orthobiologics and BD | M Exercise | 2022-01-01 | 2022-01-04 | 3,564 | — | $0 | 116,031 | SEC↗ |
| Valentine Keith | Chief Executive Officer | J Other | 2021-12-31 | 2022-01-04 | 1,026 | $8.92 | $9.2K | 305,196 | SEC↗ |
| Winge John J. | Vice President, Sales | J Other | 2021-12-31 | 2022-01-04 | 521 | $11.58 | $6.0K | 77,910 | SEC↗ |
| Steinway Angela | Director | A Award | 2021-12-14 | 2021-12-15 | 7,782 | — | $0 | 7,782 | SEC↗ |
| BRADLEY KEITH | Director | F Tax w/h | 2021-12-02 | 2021-12-03 | 37 | $13.38 | $495 | 73,005 | SEC↗ |
| BRADLEY KEITH | Director | F Tax w/h | 2021-09-02 | 2021-09-03 | 37 | $16.95 | $627 | 73,042 | SEC↗ |
| FEKETE MICHAEL | Director | P Buy | 2021-08-20 | 2021-09-02 | 10,000 | $14.80 | $148.0K | 88,370 | SEC↗ |
| Standish Beau | President, Enabling Tech | S Sale | 2021-07-21 | 2021-07-23 | 10,100 | $19.24 | $194.3K | 0 | SEC↗ |
| Standish Beau | President, Enabling Tech | S Sale | 2021-07-16 | 2021-07-19 | 8,054 | $19.24 | $155.0K | 10,100 | SEC↗ |
| Standish Beau | President, Enabling Tech | S Sale | 2021-07-15 | 2021-07-19 | 18,154 | $18.83 | $341.8K | 18,154 | SEC↗ |
| Cirino Dennis | SVP, Global Spinal Systems | M Exercise deriv | 2021-07-02 | 2021-07-02 | 13,207 | — | $0 | 0 | SEC↗ |
| Cirino Dennis | SVP, Global Spinal Systems | F Tax w/h | 2021-07-02 | 2021-07-02 | 4,567 | $20.23 | $92.4K | 37,545 | SEC↗ |
| Cirino Dennis | SVP, Global Spinal Systems | M Exercise | 2021-07-02 | 2021-07-02 | 13,207 | — | $0 | 42,112 | SEC↗ |
| BRADLEY KEITH | Director | F Tax w/h | 2021-06-30 | 2021-07-02 | 36 | $20.51 | $738 | 73,079 | SEC↗ |
| BRADLEY KEITH | Director | A Award | 2021-06-30 | 2021-07-02 | 792 | — | $0 | 73,115 | SEC↗ |
| ESSIG STUART | Director | A Award | 2021-06-30 | 2021-07-02 | 1,097 | — | $0 | 444,332 | SEC↗ |
| Gaeta Renee | Director | A Award | 2021-06-30 | 2021-07-02 | 609 | — | $0 | 26,113 | SEC↗ |
| Stephenson Kirtley C. | Director | A Award | 2021-06-30 | 2021-07-02 | 914 | — | $0 | 106,319 | SEC↗ |
| Valentine Keith | Chief Executive Officer | J Other | 2021-06-30 | 2021-07-02 | 1,356 | $8.92 | $12.1K | 304,170 | SEC↗ |
| Lipschultz Tyler | SVP, Orthobiologics and BD | J Other | 2021-06-30 | 2021-07-02 | 2,383 | $8.92 | $21.3K | 112,467 | SEC↗ |
| Cirino Dennis | SVP, Global Spinal Systems | J Other | 2021-06-30 | 2021-07-02 | 2,383 | $8.92 | $21.3K | 28,905 | SEC↗ |
| BRADLEY KEITH | Director | F Tax w/h | 2021-06-03 | 2021-06-04 | 382 | $20.28 | $7.7K | 72,323 | SEC↗ |
| Standish Beau | President, Enabling Tech | A Award deriv | 2021-06-02 | 2021-06-04 | 100,000 | — | $0 | 100,000 | SEC↗ |
| BRADLEY KEITH | Director | A Award | 2021-06-02 | 2021-06-04 | 6,253 | — | $0 | 69,454 | SEC↗ |
| BRADLEY KEITH | Director | A Award | 2021-06-02 | 2021-06-04 | 3,251 | — | $0 | 72,705 | SEC↗ |
| ESSIG STUART | Director | A Award | 2021-06-02 | 2021-06-04 | 6,253 | — | $0 | 443,235 | SEC↗ |
| FEKETE MICHAEL | Director | A Award | 2021-06-02 | 2021-06-04 | 3,001 | — | $0 | 78,370 | SEC↗ |
| FEKETE MICHAEL | Director | A Award | 2021-06-02 | 2021-06-04 | 6,253 | — | $0 | 75,369 | SEC↗ |
| Gaeta Renee | Director | A Award | 2021-06-02 | 2021-06-04 | 6,253 | — | $0 | 25,504 | SEC↗ |
| HENNEMAN JOHN B III | Director | A Award | 2021-06-02 | 2021-06-04 | 6,253 | — | $0 | 66,711 | SEC↗ |
| Maniar Shweta | Director | A Award | 2021-06-02 | 2021-06-04 | 6,253 | — | $0 | 11,836 | SEC↗ |
| Stephenson Kirtley C. | Director | A Award | 2021-06-02 | 2021-06-04 | 8,754 | — | $0 | 105,405 | SEC↗ |
| Maniar Shweta | Director | A Award | 2021-04-01 | 2021-04-01 | 5,583 | — | $0 | 5,583 | SEC↗ |
| BRADLEY KEITH | Director | A Award | 2021-03-31 | 2021-04-01 | 933 | — | $0 | 63,243 | SEC↗ |
| BRADLEY KEITH | Director | F Tax w/h | 2021-03-31 | 2021-04-01 | 42 | $17.40 | $731 | 63,201 | SEC↗ |
| Stephenson Kirtley C. | Director | A Award | 2021-03-31 | 2021-04-01 | 1,077 | — | $0 | 96,651 | SEC↗ |
| ESSIG STUART | Director | A Award | 2021-03-31 | 2021-04-01 | 1,293 | — | $0 | 436,982 | SEC↗ |
| Gaeta Renee | Director | A Award | 2021-03-31 | 2021-04-01 | 718 | — | $0 | 19,251 | SEC↗ |
| Gaeta Renee | Director | S Sale | 2021-03-08 | 2021-03-08 | 2,920 | $18.28 | $53.4K | 18,533 | SEC↗ |
| Gaeta Renee | Director | S Sale | 2021-02-22 | 2021-02-23 | 3,000 | $17.76 | $53.3K | 21,453 | SEC↗ |
| Valentine Keith | Chief Executive Officer | A Award deriv | 2021-01-28 | 2021-01-29 | 261,699 | — | $0 | 261,699 | SEC↗ |
| Valentine Keith | Chief Executive Officer | A Award deriv | 2021-01-28 | 2021-01-29 | 78,588 | — | $0 | 78,588 | SEC↗ |
| Keran Patrick L | VP, General Counsel | A Award deriv | 2021-01-28 | 2021-01-29 | 40,786 | — | $0 | 40,786 | SEC↗ |
| Keran Patrick L | VP, General Counsel | A Award deriv | 2021-01-28 | 2021-01-29 | 12,248 | — | $0 | 12,248 | SEC↗ |
| Bostjancic John J. | Chief Financial Officer | A Award deriv | 2021-01-28 | 2021-01-29 | 20,759 | — | $0 | 20,759 | SEC↗ |
| Bostjancic John J. | Chief Financial Officer | A Award deriv | 2021-01-28 | 2021-01-29 | 69,128 | — | $0 | 69,128 | SEC↗ |
| Winge John J. | Vice President, Sales | A Award deriv | 2021-01-28 | 2021-01-29 | 21,648 | — | $0 | 21,648 | SEC↗ |
| Cirino Dennis | SVP, Global Spinal Systems | A Award deriv | 2021-01-28 | 2021-01-29 | 19,652 | — | $0 | 19,652 | SEC↗ |
| Cirino Dennis | SVP, Global Spinal Systems | A Award deriv | 2021-01-28 | 2021-01-29 | 17,705 | — | $0 | 17,705 | SEC↗ |
| Lipschultz Tyler | SVP, Orthobiologics and BD | A Award deriv | 2021-01-28 | 2021-01-29 | 19,454 | — | $0 | 19,454 | SEC↗ |
| Lipschultz Tyler | SVP, Orthobiologics and BD | A Award deriv | 2021-01-28 | 2021-01-29 | 16,196 | — | $0 | 16,196 | SEC↗ |
| Valentine Keith | Chief Executive Officer | M Exercise deriv | 2021-01-01 | 2021-01-05 | 27,428 | — | $0 | 0 | SEC↗ |
| Valentine Keith | Chief Executive Officer | M Exercise deriv | 2021-01-01 | 2021-01-05 | 7,788 | — | $0 | 7,789 | SEC↗ |
| Valentine Keith | Chief Executive Officer | M Exercise deriv | 2021-01-01 | 2021-01-05 | 12,183 | — | $0 | 24,366 | SEC↗ |
| Lipschultz Tyler | SVP, Orthobiologics and BD | M Exercise deriv | 2021-01-01 | 2021-01-05 | 8,362 | — | $0 | 16,724 | SEC↗ |
| Lipschultz Tyler | SVP, Orthobiologics and BD | M Exercise deriv | 2021-01-01 | 2021-01-05 | 3,564 | — | $0 | 3,564 | SEC↗ |
| Lipschultz Tyler | SVP, Orthobiologics and BD | M Exercise deriv | 2021-01-01 | 2021-01-05 | 12,551 | — | $0 | 0 | SEC↗ |
| Bostjancic John J. | Chief Financial Officer | M Exercise deriv | 2021-01-01 | 2021-01-05 | 5,574 | — | $0 | 11,150 | SEC↗ |
| Bostjancic John J. | Chief Financial Officer | M Exercise deriv | 2021-01-01 | 2021-01-05 | 12,551 | — | $0 | 0 | SEC↗ |
| Bostjancic John J. | Chief Financial Officer | M Exercise deriv | 2021-01-01 | 2021-01-05 | 5,346 | — | $0 | 5,346 | SEC↗ |
| Keran Patrick L | VP, General Counsel | M Exercise deriv | 2021-01-01 | 2021-01-05 | 5,279 | — | $0 | 10,560 | SEC↗ |
| Keran Patrick L | VP, General Counsel | M Exercise deriv | 2021-01-01 | 2021-01-05 | 11,886 | — | $0 | 0 | SEC↗ |
| Keran Patrick L | VP, General Counsel | M Exercise deriv | 2021-01-01 | 2021-01-05 | 3,375 | — | $0 | 3,375 | SEC↗ |
| Cirino Dennis | SVP, Global Spinal Systems | M Exercise deriv | 2021-01-01 | 2021-01-05 | 5,352 | — | $0 | 10,704 | SEC↗ |
| Cirino Dennis | SVP, Global Spinal Systems | M Exercise deriv | 2021-01-01 | 2021-01-05 | 3,421 | — | $0 | 3,422 | SEC↗ |
| Winge John J. | Vice President, Sales | M Exercise deriv | 2021-01-01 | 2021-01-05 | 4,868 | — | $0 | 9,736 | SEC↗ |
| Winge John J. | Vice President, Sales | M Exercise deriv | 2021-01-01 | 2021-01-05 | 3,112 | — | $0 | 3,112 | SEC↗ |
| Winge John J. | Vice President, Sales | M Exercise deriv | 2021-01-01 | 2021-01-05 | 10,959 | — | $0 | 0 | SEC↗ |
| Valentine Keith | Chief Executive Officer | M Exercise | 2021-01-01 | 2021-01-05 | 12,183 | — | $0 | 328,264 | SEC↗ |
| Valentine Keith | Chief Executive Officer | M Exercise | 2021-01-01 | 2021-01-05 | 27,428 | — | $0 | 308,293 | SEC↗ |
| Valentine Keith | Chief Executive Officer | M Exercise | 2021-01-01 | 2021-01-05 | 7,788 | — | $0 | 316,081 | SEC↗ |
| Valentine Keith | Chief Executive Officer | F Tax w/h | 2021-01-01 | 2021-01-05 | 25,450 | $17.45 | $444.1K | 302,814 | SEC↗ |
| Lipschultz Tyler | SVP, Orthobiologics and BD | F Tax w/h | 2021-01-01 | 2021-01-05 | 11,349 | $17.45 | $198.0K | 110,084 | SEC↗ |
| Lipschultz Tyler | SVP, Orthobiologics and BD | M Exercise | 2021-01-01 | 2021-01-05 | 8,362 | — | $0 | 121,433 | SEC↗ |
| Lipschultz Tyler | SVP, Orthobiologics and BD | M Exercise | 2021-01-01 | 2021-01-05 | 3,564 | — | $0 | 113,071 | SEC↗ |
| Lipschultz Tyler | SVP, Orthobiologics and BD | M Exercise | 2021-01-01 | 2021-01-05 | 12,551 | — | $0 | 109,507 | SEC↗ |
| Bostjancic John J. | Chief Financial Officer | M Exercise | 2021-01-01 | 2021-01-05 | 5,346 | — | $0 | 99,774 | SEC↗ |
| Bostjancic John J. | Chief Financial Officer | M Exercise | 2021-01-01 | 2021-01-05 | 5,574 | — | $0 | 105,348 | SEC↗ |
| Bostjancic John J. | Chief Financial Officer | F Tax w/h | 2021-01-01 | 2021-01-05 | 12,851 | $17.45 | $224.2K | 92,497 | SEC↗ |
| Bostjancic John J. | Chief Financial Officer | M Exercise | 2021-01-01 | 2021-01-05 | 12,551 | — | $0 | 94,428 | SEC↗ |
| Keran Patrick L | VP, General Counsel | M Exercise | 2021-01-01 | 2021-01-05 | 3,375 | — | $0 | 74,156 | SEC↗ |
| Keran Patrick L | VP, General Counsel | M Exercise | 2021-01-01 | 2021-01-05 | 11,886 | — | $0 | 70,781 | SEC↗ |
| Keran Patrick L | VP, General Counsel | M Exercise | 2021-01-01 | 2021-01-05 | 5,279 | — | $0 | 79,435 | SEC↗ |
| Keran Patrick L | VP, General Counsel | F Tax w/h | 2021-01-01 | 2021-01-05 | 11,308 | $17.45 | $197.3K | 68,127 | SEC↗ |
| Cirino Dennis | SVP, Global Spinal Systems | F Tax w/h | 2021-01-01 | 2021-01-05 | 5,137 | $17.45 | $89.6K | 26,522 | SEC↗ |
| Cirino Dennis | SVP, Global Spinal Systems | M Exercise | 2021-01-01 | 2021-01-05 | 3,421 | — | $0 | 26,307 | SEC↗ |
| Cirino Dennis | SVP, Global Spinal Systems | M Exercise | 2021-01-01 | 2021-01-05 | 5,352 | — | $0 | 31,659 | SEC↗ |
| Winge John J. | Vice President, Sales | M Exercise | 2021-01-01 | 2021-01-05 | 10,959 | — | $0 | 78,499 | SEC↗ |
| Winge John J. | Vice President, Sales | M Exercise | 2021-01-01 | 2021-01-05 | 3,112 | — | $0 | 81,611 | SEC↗ |
| Winge John J. | Vice President, Sales | M Exercise | 2021-01-01 | 2021-01-05 | 4,868 | — | $0 | 86,479 | SEC↗ |
| Winge John J. | Vice President, Sales | F Tax w/h | 2021-01-01 | 2021-01-05 | 9,090 | $17.45 | $158.6K | 77,389 | SEC↗ |
| Stephenson Kirtley C. | Director | A Award | 2020-12-31 | 2021-01-04 | 1,074 | — | $0 | 95,574 | SEC↗ |
| ESSIG STUART | Director | A Award | 2020-12-31 | 2021-01-04 | 1,289 | — | $0 | 435,689 | SEC↗ |
| BRADLEY KEITH | Director | A Award | 2020-12-31 | 2021-01-04 | 931 | — | $0 | 62,352 | SEC↗ |
| BRADLEY KEITH | Director | F Tax w/h | 2020-12-31 | 2021-01-04 | 42 | $17.45 | $733 | 62,310 | SEC↗ |
| Gaeta Renee | Director | A Award | 2020-12-31 | 2021-01-04 | 716 | — | $0 | 24,453 | SEC↗ |
| Valentine Keith | Chief Executive Officer | J Other | 2020-12-31 | 2021-01-05 | 1,058 | $8.92 | $9.4K | 280,865 | SEC↗ |
| Lipschultz Tyler | SVP, Orthobiologics and BD | J Other | 2020-12-31 | 2021-01-05 | 1,134 | $8.92 | $10.1K | 96,956 | SEC↗ |